Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
-
SOUTH SAN FRANCISCO, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated...
-
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
-
Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE...
-
Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE...
-
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
-
ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases,...
-
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
-
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
-
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...